- Trials with a EudraCT protocol (370)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
370 result(s) found for: Nursing diagnosis.
Displaying page 1 of 19.
EudraCT Number: 2006-000860-10 | Sponsor Protocol Number: 10729 | Start Date*: 2006-06-30 |
Sponsor Name:H. Lundbeck A/S | ||
Full Title: An Open-Label Study Investigating the Specific Effects of Memantine in Institutionalised Patients with Alzheimer’s Disease | ||
Medical condition: Effects of memantine treatment in institutionalised patients with Alzheimer's Disease. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FI (Prematurely Ended) BE (Completed) GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001251-41 | Sponsor Protocol Number: P20/05 | Start Date*: 2020-04-17 | |||||||||||
Sponsor Name:CH de Versailles | |||||||||||||
Full Title: A PROOF OF CONCEPT STUDY TESTING THE VALUE OF IMATINIB IN PREVENTION OF COVID-19 IN AGED PATIENTS. | |||||||||||||
Medical condition: Aged patients at risk of COVID-19 infection | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000863-98 | Sponsor Protocol Number: GlucoTab@MobileCare | Start Date*: 2018-06-25 | |||||||||||
Sponsor Name:Medical University of Graz | |||||||||||||
Full Title: A single-centre, open-label, non-controlled trial of acceptance, usability, safety and efficacy of a tablet based workflow and decision support system with incorporated basal-insulin algorithm for ... | |||||||||||||
Medical condition: Diabetes mellitus type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003866-14 | Sponsor Protocol Number: B5091007 | Start Date*: 2017-06-15 | ||||||||||||||||
Sponsor Name:Pfizer Inc. | ||||||||||||||||||
Full Title: A Phase 3, Placebo-Controlled, Randomized, Observer-Blinded Study To Evaluate The Efficacy, Safety, And Tolerability Of A Clostridium Difficile Vaccine In Adults 50 Years Of Age And Older | ||||||||||||||||||
Medical condition: Primary C difficile infection (CDI) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SK (Completed) BG (Completed) SE (Completed) HU (Completed) BE (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) DE (Completed) FI (Completed) PT (Completed) ES (Completed) PL (Completed) FR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-020008-31 | Sponsor Protocol Number: ACP-103-019 | Start Date*: 2013-10-25 |
Sponsor Name:ACADIA Pharmaceuticals Inc | ||
Full Title: A Single center, Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Psychosis in Alzheimer’s Disease | ||
Medical condition: Psychosis associated with Alzheimer's disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-000287-84 | Sponsor Protocol Number: 101 | Start Date*: 2006-07-11 | |||||||||||
Sponsor Name:Sykehuset Innlandet HF | |||||||||||||
Full Title: Seponering av antipsykotika og antidepressiva hos demente pasienter med APSD i sykehjem - en åpen studie. | |||||||||||||
Medical condition: The included patients are all elderly people with dementia of Alzheimer or vascular type. Their dementia is moderate or severe and they all have Behavioral or Psychological Symptomes (BPSD). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-004412-70 | Sponsor Protocol Number: A3051054 | Start Date*: 2007-07-25 | |||||||||||
Sponsor Name:PFIZER | |||||||||||||
Full Title: A 12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL WITH 40-WEEK FOLLOW-UP EVALUATING THE SAFETY AND EFFICACY OF VARENICLINE TARTRATE FOR SMOKING CESSATION IN PATIENTS WIT... | |||||||||||||
Medical condition: Smoking Cessation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-008238-35 | Sponsor Protocol Number: AMLSG11-08 | Start Date*: 2009-06-24 |
Sponsor Name:Universitätsklinikum Ulm | ||
Full Title: Open-Label, Multicenter Phase II Study For the Evaluation of Dasatinib (Sprycel™) Following Induction and Consolidation Therapy as well as in Maintenance Therapy in Patients With Newly Diagnosed Co... | ||
Medical condition: Newly diagnosed core binding factor acute myeloid leukemia. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-002707-33 | Sponsor Protocol Number: GS-US-352-0101 | Start Date*: 2014-05-27 | |||||||||||
Sponsor Name:Sierra Oncology, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects with Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post- Essential Thromboc... | |||||||||||||
Medical condition: Primary Myleofibrosis (PMF) or post-Polycythemia vera or post-Essential Thrombocythemia Myelofibrosis (post-PV/ET MF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) DE (Completed) BE (Completed) GB (Completed) AT (Completed) SE (Completed) ES (Completed) HU (Completed) NL (Completed) DK (Completed) BG (Completed) RO (Completed) PL (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001056-17 | Sponsor Protocol Number: 3606 | Start Date*: 2020-08-14 | ||||||||||||||||
Sponsor Name:Kings's College London
[...]
1. Kings's College London
2. South London and Maudsley NHS Foundation Trust |
||||||||||||||||||
Full Title: A randomised feasibility trial investigating Sativex® for the treatment of the Agitation & Aggression (A/A) in Alzheimer’s Dementia. | ||||||||||||||||||
Medical condition: Clinically significant agitation in Alzheimer's Diseases | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003168-37 | Sponsor Protocol Number: Thllo | Start Date*: 2019-05-13 |
Sponsor Name:University Tuebingen | ||
Full Title: Therapeutic Iloprost for the treatment of Acute Respiratory Distress Syndrome (ARDS) (the ThIlo-Trial): a prospective, randomized, multicenter phase II study | ||
Medical condition: Acute respiratory distress syndrome requiring mechanical ventilation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-004918-14 | Sponsor Protocol Number: A2501056 | Start Date*: 2008-05-06 | |||||||||||
Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York,NY 10017 | |||||||||||||
Full Title: A 12-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE IMPACT OF DONEPEZIL HYDROCHLORIDE (ARICEPT®) ON BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS IN PATIENTS WITH SEVERE ALZHEIMER’S DISEASE | |||||||||||||
Medical condition: SEVERE ALZHEIMER’S DISEASE | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014916-37 | Sponsor Protocol Number: A3051122 | Start Date*: 2010-03-15 | |||||||||||
Sponsor Name:PFIZER | |||||||||||||
Full Title: "Estudio de fase 4, doble ciego, controlado con placebo, multicéntrico y de 12 semanas de duración para evaluar la seguridad y la eficacia del tartrato de Vareniclina (CP-526,555) 1 mg dos veces a... | |||||||||||||
Medical condition: "Dejar de Fumar" "Smoking cessation" | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) DE (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000042-22 | Sponsor Protocol Number: PI16/00720 | Start Date*: 2017-05-11 |
Sponsor Name:GAP MALLORCA | ||
Full Title: Randomized, pragmátic, open-label clinical trial with blind evaluator, to evaluate the efficacy efficacy of continuing drug treatment in patients with advanced dementia. | ||
Medical condition: Advanced dementia | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2009-012218-30 | Sponsor Protocol Number: ML22648 | Start Date*: 2009-10-06 |
Sponsor Name:Roche Farmacêutica Química, Lda. | ||
Full Title: A randomized, double-blind, placebo-controlled study to assess the efficacy of tocilizumab (TCZ) + non-biological DMARD in reducing synovitis as measured by magnetic resonance imaging (MRI) at 12 w... | ||
Medical condition: Men and women > 18 years of age with RA who are currently experiencing an inadequate clinical response to a stable dose of non-biologic DMARDs (at least 12 weeks) and with MRI documented synovitis ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: PT (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-002782-37 | Sponsor Protocol Number: ENT05 | Start Date*: 2005-11-17 |
Sponsor Name:Heart of England NHS Foundation Trust | ||
Full Title: A Randomised Trial of Inhaled Entonox Plus Local Anaesthesia Versus Intravenous Midazolam Plus Local Anaesthesia To Improve Pain Control During Bone Marrow Biopsy | ||
Medical condition: This study will involve a group of patients requiring diagnostic bone marrow aspiration and biopsy. The reasons for these will include haematological abnormalities of the blood count , which may be... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-003887-39 | Sponsor Protocol Number: P1200_46 | Start Date*: 2020-10-29 |
Sponsor Name:Cliniques universitaires Saint-Luc | ||
Full Title: Molecular effects of Apremilast (Otezal) in synovial biopsies of patients with psoriatic arthisis | ||
Medical condition: Psoriasis and Psoriatic Arthritis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-003138-17 | Sponsor Protocol Number: P1200_51 | Start Date*: 2020-01-17 | |||||||||||
Sponsor Name:Cliniques universitaires Saint-Luc | |||||||||||||
Full Title: A 24 weeks proof of concept study to evaluate the clinical, MRI and synovial tissue benefit of Sarilumab in active RA patients despite TNF agents | |||||||||||||
Medical condition: Medical condition – Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-002844-93 | Sponsor Protocol Number: 6002-INT-001 | Start Date*: 2005-02-08 |
Sponsor Name:Kyowa Hakko U.K. Limited | ||
Full Title: A Long-Term, Multicenter, Open-Label Safety Study with Oral 20 or 40 mg/d Doses of KW-6002 (Istradefylline) as Treatment for Parkinson’s Disease in Patients with Motor Response Complications on Lev... | ||
Medical condition: Parkinson's Disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: LT (Completed) LV (Completed) GB (Completed) EE (Completed) AT (Completed) IT (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-003117-18 | Sponsor Protocol Number: AMLSG21-13 | Start Date*: 2014-07-14 |
Sponsor Name:University Hospital Ulm | ||
Full Title: Randomized Phase III Study of Intensive Chemotherapy with or without Dasatinib (Sprycel™) in Adult Patients with Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) AMLSG 21-13 | ||
Medical condition: Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) AT (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
